1. Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases
- Author
-
Matthew D. Hirschey, Angelical Martin, and Kathleen A. Hershberger
- Subjects
0301 basic medicine ,chemistry.chemical_classification ,Kidney ,biology ,business.industry ,Nicotinamide adenine dinucleotide ,Pharmacology ,Mitochondrion ,Cofactor ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,Enzyme ,medicine.anatomical_structure ,chemistry ,Nephrology ,Sirtuin ,biology.protein ,medicine ,NAD+ kinase ,Signal transduction ,business - Abstract
The coenzyme nicotinamide adenine dinucleotide (NAD+) has key roles in the regulation of redox status and energy metabolism. NAD+ depletion is emerging as a major contributor to the pathogenesis of cardiac and renal diseases and NAD+ repletion strategies have shown therapeutic potential as a means to restore healthy metabolism and physiological function. The pleotropic roles of NAD+ enable several possible avenues by which repletion of this coenzyme could have therapeutic efficacy. In particular, NAD+ functions as a co-substrate in deacylation reactions carried out by the sirtuin family of enzymes. These NAD+-dependent deacylases control several aspects of metabolism and a wealth of data suggests that boosting sirtuin activity via NAD+ supplementation might be a promising therapy for cardiac and renal pathologies. This Review summarizes the role of NAD+ metabolism in the heart and kidney, and highlights the mitochondrial sirtuins as mediators of some of the beneficial effects of NAD+-boosting therapies in preclinical animal models. We surmise that modulating the NAD+-sirtuin axis is a clinically relevant approach to develop new therapies for cardiac and renal diseases.
- Published
- 2017
- Full Text
- View/download PDF